Surfactant administration via a supraglottic airway device or laryngeal mask airway (SALSA) is a minimally invasive method of instilling surfactant in the trachea during spontaneous breathing and after applying nasal continuous positive airway pressure (nCPAP). However, the procedure has been limited from use in very low birth weight neonates, due to lack of preterm size LMAs, which are now emerging on the market. The goal of this study is to see if investigators can successfully use a new, smaller laryngeal mask airway (LMA) to place and give surfactant to premature babies with respiratory distress syndrome (RDS) who weigh between 750g and 1500g at birth. The main objectives of the study are to: * Check the placement of the new, smaller LMA: This includes evaluating the airway, how long it takes to place the LMA, how many attempts are needed, and the baby's stability during the process. * Evaluate the administration of surfactant using the new LMA: Investigators will look at how the baby responds clinically, any changes in oxygen needs, how many doses of surfactant are required, the level of respiratory support needed, and whether intubation or mechanical ventilation is necessary. * Ensure the safety of using the new LMA and administering surfactant: Investigators will monitor the baby's stability during the procedure and watch for any adverse events. * Assess pain during the procedure: Investigators will evaluate pain levels using a pain scale based on video reviews. Above objectives of feasibility are to be assessed before proceeding to a large randomize clinical trial assessing effectiveness and safety.
Methodology Feasibility will be measure by a combination of real-life observations of the procedure and video-review with synced physiological data (oxygen saturation and heart rate). Study Site The Phu San Hanoi Hospital, the largest obstetric hospital in northern Vietnam, receives about 40.000 births annually and has a level-III neonatal intensive care unit with capacity of approximately 40 neonates. Approximately 10-15 neonates weighing less than 1500g per month are admitted who receives standard surfactant treatment with IN-tubation-SURfactant-Extubation (INSURE).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
While the child is spontaneously breathing on nasal CPAP treatment, the neonatal intensive care (NICU) physician will place the LMA and assess for adequate airway by CO2-detection, chest movement, pulmonary auscultation of bilateral breath sounds, gastric insufflation, oxygen saturation and heart rate. A placement attempt should not last more than 30 seconds. Surfactant will be administered slowly in 1-2 ml aliquots (Curosurf 200 mg/kg) via an appropriate size laryngeal mask airway. The neonate should primarily be spontaneously breathing and if needed receives gentle supportive positive pressure ventilation (PPV). Gentle supportive PPV is given for 30 seconds after surfactant is administered, before LMA is removed.
Phu San Hanoi Hospital - Hanoi Obstetrics and Gynecology Hospital
Hanoi, Vietnam
Successful LMA placement, with signs of adequate airway, allowing two attempts.
Categorical variable (Yes/No) A successful placement attempt is defined as insertion of the LMA into the infant's mouth with signs of adequate airway, as per judgement of the physician performing the procedure. Factors that will be considered are carbon dioxide (CO2)-detection, chest movement, pulmonary auscultation of bilateral breath sounds, oxygen saturation and heart rate.
Time frame: During procedure. 0-30 minutes.
Confirmation of carbon dioxide on carbon dioxide detector
Categorical (Yes/No)
Time frame: During procedure. 0-30 minutes.
Chest rise during LMA placement
Categorical (Yes/No)
Time frame: During procedure 0-30 minutes.
Bilateral breath sounds by auscultation during LMA placement
Categorical (Yes/No)
Time frame: During procedure. 0-30 minutes.
Number of attempts required for successful placement
Numerical variable.
Time frame: During procedure. 0-30 minutes.
Attempt duration more than 30 seconds
Categorical variable (Yes/No)
Time frame: During procedure. 0-30 minutes.
Duration of each LMA placement attempt
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Time between attempts
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Fluctuations in heart rate during placement
Numerical variable (beats per minute). Difference between mean/median at baseline and during placement. Measured by pulse oximetry.
Time frame: During procedure. 0-30 minutes.
Fluctuations in oxygen saturation (SpO2) during placement
Numerical variable (percentage). Difference between mean/median at baseline and during placement. Measured by pulse oximetry.
Time frame: During procedure. 0-30 minutes.
Fluctuations in heart rate during surfactant administration
Numerical variable (beats per minute). Difference between mean/median at baseline and during surfactant administration. Measured by pulse oximetry.
Time frame: During procedure. 0-30 minutes.
Fluctuations in oxygen saturation (SpO2) during surfactant administration
Numerical variable (percentage). Difference between mean/median at baseline and during surfactant administration Measured by pulse oximetry.
Time frame: During procedure. 0-30 minutes.
Duration of SpO2 less than 80%
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of SpO2 less than 60%
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of SpO2 less than 40%
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of heart rate less than 100 beats per minute (bpm)
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of heart rate less than 60 beats per minute (bpm)
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Number of bradycardia less than 60 bpm for more than 10 seconds
Numerical variable.
Time frame: During procedure. 0-30 minutes.
Number of desaturations to less 80% for more than 30 seconds
Numerical variable.
Time frame: During procedure. 0-30 minutes.
Number of apneas lasting more than 20 seconds
Numerical variable
Time frame: During procedure. 0-30 minutes.
Volume of surfactant in gastric residuals after the procedure
Numerical variable (milliliters)
Time frame: During procedure. 0-30 minutes.
Total procedure duration
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of positive pressure ventilation during LMA placement
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of positive pressure ventilation during surfactant administration
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Duration of positive pressure ventilation during procedure
Numerical variable (seconds)
Time frame: During procedure. 0-30 minutes.
Fraction of inspired oxygen
Oxygen requirement to maintain SpO2 between 90-95%. Measured before start of procedure and at 5 minutes , 15 minutes , 30 minutes and 1 hour post-procedure.
Time frame: 10 minutes before procedure until 1 hour after procedure.
Need for early redosing of surfactant
Categorical (Yes/No)
Time frame: Within 6 hours from first surfactant administration
Need for invasive mechanical ventilation within 72 hours
Categorical (Yes/No)
Time frame: Within 72 hours after surfactant administration
Death
Categorical (Yes/No)
Time frame: Within 7 days after birth
Duration of oxygen requirement after surfactant administration
Numerical (hours)
Time frame: Within 7 days after birth
Duration of continuous positive airway pressure (CPAP) after surfactant administration
Numerical variable (hours)
Time frame: Within 7 days after birth
Duration of non-invasive positive pressure ventilation (NIPPV) after surfactant administration
Numerical variable (hours)
Time frame: Within 7 days after birth
Duration of invasive mechanical ventilation after surfactant administration
Numerical variable (hours)
Time frame: Within 7 days after birth
Number of surfactant doses given
Numerical variable
Time frame: Within 7 days after birth
Need for subsequent intubation and mechanical ventilation
Categorical variable (Yes/No)
Time frame: Within 7 days after birth
Administration method for subsequent surfactant doses
Categorical. (Surfactant via laryngeal mask airway OR Surfactant via Intubation-Surfactant-Extubation OR Surfactant via intubation followed by mechanical ventilation)
Time frame: Within 7 days after birth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.